Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl
NCT ID: NCT01062191
Last Updated: 2011-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
3 participants
INTERVENTIONAL
2007-05-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites
NCT01062204
Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing
NCT05424354
Aquacel Hypersensitivity Dressing in TJAs
NCT06011629
Comparison of Skin Substitutes Used in Burn Care
NCT00676013
A Randomized Comparison Study of Aquacel Ag and Glucan II as Donor Site Dressings
NCT00581217
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Primary Investigator will first identify the study site and control site for each patient and take the initial measurements. Trained personnel will apply the bandage to the study site. No secondary bandage will be applied. Typical meticulous wound care and adequate analgesic medical coverage will be provided for the duration of the study. Both the patient and medical staff will be trained on patient use instructions for the dressing. The patients will be monitored for a short time after application of the bandage as part of standard procedure, and the patient is then allowed to go home with instructions for care. Within 2-8 days after application, the dressing will be inspected and range of motion will be measured for both the study site and the control site. Any concomitant treatment (medications, wound care) will be thoroughly documented for the duration of the study. Both dressings are designed to remain on the wound until the bandage falls off, which indicates re-epithelialization of the wound. The dressings should not be removed by the patient or medical staff unless there are signs of infection, deterioration of bandage, or other adverse event. If the bandage falls off, the patient is instructed to immediately call the medical staff.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
Nanoflex Powder Dressing applied to joint
Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
Wound dressing
Aquacel AG, typical carboxymethylcellulose dressing
Sodium CMC dressing control applied to joint
Aquacel AG, typical carboxymethylcellulose dressing
4" X 4", Aquacel silver sheet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aquacel AG, typical carboxymethylcellulose dressing
4" X 4", Aquacel silver sheet
Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
Wound dressing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient is in general good health;
3. Patient has partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints;
4. Patient has one unburned contralateral joint without major internal or external joint derangement to be used as control
5. Patient is willing and able to cooperate with the protocol for 30 days
6. Patient is capable of provided informed consent
7. Patient provides authorization for use and disclosure of protected health information
Exclusion Criteria
2. Patient has superficial or full thickness burn wounds;
3. Patient has acutely infected wounds;
4. Patient has wounds with surrounding cellulites;
5. Patient has a history of hypersensitivity to any components of either the nanoparticle or sodium hydrocellulose dressing, or any know sensitivities to other hydrogel bandage treatments
6. Patient has a concurrent clinical condition, which in the judgment of the Investigator cold either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study;
7. Patient is wearing any type of orthopedic device that may come in contact with the dressing;
8. Patient has history of poor wound healing, history of smoking, history of drug/alcohol abuse, any other skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination
9. Patient has wound originating from chronic condition
10. Patients with history of any immunodeficiency syndrome or condition
11. Patients who have applied any dressing or medication (OTC or prescription) to the wound (within 48 hours of study? )
12. Patient has participated in a clinical research study within the last 30 days prior to enrollment;
13. Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
2 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ULURU Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UTSW Medical Center, Department of Physical Medicine and Rehabilitation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT Southwestern
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U-C-6U1101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.